UROVANT SCIENCES INC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.2M
Doctors Paid
9,422
Transactions
38,771
2022 Total
$7.2M
Payment Breakdown by Category
Research$7.0M (75.6%)
Food & Beverage$767,926 (8.3%)
Consulting$305,443 (3.3%)
Travel$232,117 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 1,070 | 75.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $924,862 | 502 | 10.0% |
| Food and Beverage | $767,926 | 35,981 | 8.3% |
| Consulting Fee | $305,443 | 158 | 3.3% |
| Travel and Lodging | $232,117 | 963 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.1% |
| Education | $3,430 | 90 | 0.0% |
| Honoraria | $2,448 | 5 | 0.0% |
Payments by Type
Research
$7.0M
1,070 transactions
General
$2.2M
37,701 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $4.6M | 0 | 455 |
| Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | $700,844 | 0 | 251 |
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $490,024 | 0 | 110 |
| An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence | $468,080 | 0 | 225 |
| AnOpen-Label, Randomized, Crossover, Single Dose Study to Assess thePharmacokinetics and Safety of Vibegron TabletandGranuleFormulations | $426,237 | 0 | 13 |
| An open-label, randomized, croosover, single dose study to assess the pharmacokinetics and saftey of vibegron tablet and granule formulations | $230,828 | 0 | 11 |
| A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | $7,500 | 0 | 1 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur) | $5,000 | 0 | 1 |
| Composur | $1,976 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors — Page 10
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Mrs. Paige Nabors, Np, NP | Family | Fulton, MS | $368.27 | $0 |
| Ms. Saron Belay, Pa, PA | Physician Assistant | Forest Hill, MD | $367.88 | $0 |
| Sarah Enlow, Fnp-Bc, FNP-BC | Family | Tell City, IN | $367.57 | $0 |
| Ms. Melodi Lewis-Carvour, Pa-C, PA-C | Physician Assistant | Calhoun, GA | $365.04 | $0 |
| Joseph Candela, M.d, M.D | Urology | Las Vegas, NV | $364.76 | $0 |
| Susan Williams, Fnp-Bc, FNP-BC | Family | Richmond, VA | $364.62 | $0 |
| Larry Tetsoti, M.d, M.D | Urology | Brooklyn, NY | $364.08 | $0 |
| Dr. Paul Van Zijl, M.d, M.D | Urology | Bel Air, MD | $363.79 | $0 |
| Kristen Schreiber | Physician Assistant | Saint Louis, MO | $363.35 | $0 |
| Kevin Hackett, M.d, M.D | Urology | Hagerstown, MD | $362.33 | $0 |
| Chao Vang, F.n.p, F.N.P | Family | Clovis, CA | $361.00 | $0 |
| Blake Neeley, Pa-C, PA-C | Physician Assistant | Colleyville, TX | $359.55 | $0 |
| Dr. Michael Berte, Md, MD | Urology | Cleveland, OH | $358.00 | $0 |
| Katherine Riley, Pa-C, PA-C | Physician Assistant | Haymarket, VA | $355.89 | $0 |
| Dr. Mark Noller, M.d, M.D | Urology | San Jose, CA | $355.34 | $0 |
| Lawrence Newman, Md, MD | Urology | Las Vegas, NV | $355.33 | $0 |
| Brian Wade, M.d, M.D | Urology | Homewood, AL | $354.67 | $0 |
| Caitlyn Brown, Pa, PA | Physician Assistant | Monroe, NC | $352.81 | $0 |
| Matthew Burger, Pa-C, PA-C | Physician Assistant | Monroeville, PA | $352.77 | $0 |
| Dr. Bruce Woodworth, M.d, M.D | Urology | Knoxville, TN | $351.56 | $0 |
| Dr. Harold Rainwater, M.d, M.D | Urology | Fresno, CA | $351.47 | $0 |
| Milton Shaw, M.d, M.D | Internal Medicine | Boerne, TX | $351.09 | $0 |
| Beverly Tomasetti, Np, NP | Adult Health | Scranton, PA | $350.93 | $0 |
| Robert Goldfarb, M.d, M.D | Urology | Columbia, MD | $350.56 | $0 |
| Dennis Smith, Md, MD | Urology | Jeffersonville, IN | $350.29 | $0 |
About UROVANT SCIENCES INC
UROVANT SCIENCES INC has made $9.2M in payments to 9,422 healthcare providers, recorded across 38,771 transactions in the CMS Open Payments database. In 2022, the company paid $7.2M. The top product by payment volume is GEMTESA ($8.7M).
Payments were distributed across 123 medical specialties. The top specialty by payment amount is Urology ($899,546 to 3,135 doctors).
Payment categories include: Food & Beverage ($767,926), Consulting ($305,443), Research ($7.0M), Travel & Lodging ($232,117).
UROVANT SCIENCES INC is associated with 1 products in the CMS Open Payments database.